IDEXX Laboratories, Inc.

CAG Diagnostics recurring revenue (consumables, reference lab, and SaaS) dominates the portfolio, supported by multi-year reagent rental contracts and retention rates consistently in the high 90s. Total revenue grew every fiscal year FY2020-FY2025, including through the COVID-driven disruption to vet clinic operating volumes.

Companion animal diagnostics represents the substantial majority of total revenue, with the Water and Livestock, Poultry and Dairy segments collectively contributing a low single-digit share. All business lines sit within the same animal health diagnostics market, providing limited portfolio protection against a CAG-specific volume downturn.

IDEXX operates in more than 175 countries, with US revenue representing roughly half of FY2024 consolidated revenue and meaningful contributions from Europe, Asia Pacific, and other international markets. No single non-US country approaches the revenue contribution of the domestic market, placing geographic diversity near the sector average for a US-headquartered healthcare company.

The razor-and-blade model generates strong operating leverage once instruments are placed: incremental consumable and reference lab revenue runs on existing infrastructure with limited variable cost. Gross margin held approximately 60-61% across FY2021-FY2025, including through the 2022 input-cost inflation cycle, and ROIC was approximately 34% as of FY2024.

CAG Diagnostics recurring revenue is mission-critical for daily veterinary workflows: clinics run diagnostic panels for every patient visit and cannot defer without clinical impact. Multi-year reagent rental arrangements and seamless software integration anchor annual retention consistently in the high 90s across FY2021-FY2025.